Edition:
India

Revance Therapeutics Inc (RVNC.OQ)

RVNC.OQ on NASDAQ Stock Exchange Global Market

34.20USD
2:29am IST
Change (% chg)

$-1.75 (-4.87%)
Prev Close
$35.95
Open
$35.85
Day's High
$36.55
Day's Low
$34.20
Volume
114,375
Avg. Vol
79,569
52-wk High
$37.20
52-wk Low
$15.95

Select another date:

Thu, Dec 7 2017

BRIEF-Revance Announces Pricing Of Public Offering Of Common Stock

* REVANCE ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Revance Therapeutics Files For Potential Mixed Shelf Offering ‍​‍​

* REVANCE THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING ‍​‍​ Source text: (http://bit.ly/2nwJNaw) Further company coverage:

BRIEF-Revance Announces Proposed Public Offering Of Common Stock

* REVANCE THERAPEUTICS INC - PROPOSED UNDERWRITTEN PUBLIC OFFERING IN WHICH IT WILL ISSUE AND SELL APPROXIMATELY $175 MILLION OF SHARES OF ITS COMMON STOCK

BRIEF-Revance’s RT002 Meets Primary, Secondary Endpoints In Sakura Phase 3 Trials

* REVANCE’S RT002 MEETS PRIMARY AND ALL SECONDARY ENDPOINTS, ACHIEVES 6-MONTH DURATION IN PIVOTAL SAKURA PHASE 3 TRIALS FOR GLABELLAR LINES

BRIEF-Revance Plans Phase 3 Program For RT002 Injectable To Treat Cervical Dystonia

* REVANCE PLANS PHASE 3 PROGRAM FOR RT002 INJECTABLE TO TREAT CERVICAL DYSTONIA

BRIEF-Revance announces orphan drug designation of RT002 for the treatment of Cervical Dystonia

* Revance announces orphan drug designation of RT002 for the treatment of Cervical Dystonia

BRIEF-Revance Therapeutics reports qtrly net loss per share attributable to common stockholders basic and diluted‍​ $1.01

* Revance Therapeutics Inc - ‍sakura 1 & 2 phase 3 pivotal trials on track to report topline results before year-end 2017​

BRIEF-Revance completes patient enrollment in Phase 2 program for RT002 injectable

* Revance completes patient enrollment in Phase 2 program for RT002 injectable in the management of plantar fasciitis

BRIEF-Revance Q2 ‍loss per share $0.90​

* Revance Therapeutics Inc - ‍reaffirmed its financial guidance provided in January 2017​

BRIEF-Revance Therapeutics updates on phase 2 clinical trial results

* Positive Belmont phase 2 trial results published in dermatologic surgery

Select another date: